Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study
Elizabeth A. Raetz(NYU Langone Health), Peter C. Adamson(University College London), William A. Wegener(Children's Hospital of Philadelphia), Joel M. Reid(Children's Hospital of Philadelphia), Susan M. Blaney(Pediatrics and Genetics), Tarek A. Leil(Children's Hospital of Philadelphia), William L. Carroll(NYU Langone Health), Mark Krailo(Arcadia), Mitchell S. Cairo(New York Medical College), Michael J. Borowitz(Johns Hopkins University), David M. Goldenberg(Unknown)
Cited by 210
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
|Journal of Clinical Oncology|2012|1.2k
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
|Nature Genetics|2017|934